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 Introduction: A number of drugs are available for acute migraine treatment, but they
are not all effective for all patients and all attacks. The safety profiles of migraine
drugs limit their use in patients with certain comorbid conditions, and adverse effects
may also reduce the level of patient compliance.
 Areas  covered: The  different  types  of  acute  migraine  drugs  are  discussed,  with
particular regard to safety issues and potential  adverse effects. The frequent use of
analgesics, ergot alkaloids and triptans may result in the development of medication
overuse headache.
 Expert  opinion:  The  initiation  of  a  migraine  attack  is  not  fully  understood,  and
therefore  treatment  aimed  at  causative  factors is  currently  not  available.  The
tolerability and adverse effects of the drugs available at present often limit their use.
NSAIDs  are  frequently  associated  with  gastrointestinal,  and  possibly  also
cardiovascular side-effects. Ergot alkaloids may induce arterial vasoconstriction, while
the administration of triptans is contraindicated in  cardiovascular, cerebrovascular
and peripheral vascular diseases. The frequent use of these drugs poses the risk of
the  development  of  medication  overuse  headache.  There  is  a  need  for
pathomechanism-based  drugs,  and  for  the  future  achievement  of  personalized
medicine. 
Keywords: acute treatment, efficacy, migraine, safety, tolerability
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1. Introduction: Migraine is a primary headache disorder with a considerable socio-economic
and personal impact. Its exact pathomechanism has not yet been fully clarified , and there is
an ongoing debate regarding the vascular or neuronal, cortical or brainstem origin . Most of
the  drugs  used  in  migraine  therapy  are  not  disease-specific,  and  do  not  target  the
pathobiochemical basis of the disease . The primary aim of drug development is to achieve a
proactive P4 medicine that is predictive, preventive, personalized and participatory .
The adverse events (AEs) associated with the use of different drugs are an important aspect in
the daily clinical practice,  because the treatment decision must take into consideration not
only the efficacy, but also the safety of the pharmacon. AEs, tolerability AEs and safety AEs
have been defined as follows : ‘AEs are defined as any unusual event that follows medication
use.’ ‘Tolerability AEs are irritating to a patient, but are not significant in terms of morbidity
or mortality.‘ ‘Safety AEs are those side-effects that endanger a patient.’ Tolerability AEs are
important as they may influence patient compliance and adherence to a medication, whereas
safety AEs may lead to the hospitalization of the patient and may necessitate therapy. AEs are
associated with a considerable economic impact and lead to high direct and indirect costs for
the community. A multicenter retrospective cohort study revealed that AEs in hospitals  are
associated with more than USD 3,000 of adjusted additional average hospitalization cost
per AE and with an increased length of stay in the hospital . Overall direct costs related to
AEs were estimated to be of USD 21 million per 100,000 adult inhabitants per year, which
highlights the importance of AEs to the society . 
This review addresses both common and uncommon safety issues relating to the currently
available options for the acute treatment of migraine. A literature search was conducted  on
December 1, 2014 in databases of PubMed, Cochrane Central, Medline for articles related to
acute  migraine  therapy.  We  included  randomized,  double-blind,  placebo-  and/or  active-
controlled studies,  case reports  and reviews regarding medications used in acute migraine
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therapy.  Priority was given to drugs with the highest  level  of recommendation  (Level  A)
based on the European Federation of Neurological Societies (EFNS), the American Academy
of Neurology (AAN) and the American Headache Society (AHS) guidelines .
2. Acute migraine therapy
Medications used to treat acute migraine attacks can be divided in 2 groups: non-specific and
migraine-specific treatments . Non-specific medications include drugs which can be used to
treat any pain conditions, such as non-steroidal anti-inflammatory drugs (NSAIDs), opiates or
combination  of  analgesics.  Antiemetics  are  also  widely  used  to  treat  migraine-associated
symptoms; however, these treatments are also non-specific. Ergotamine, dihydroergotamine
(DHE) and triptans are considered as migraine-specific medications .
In this review, we focus only on drugs reaching level A recommendation; however, a number
of  other  medications  are  also  widely  used  by  patients  and  prescribed  by  general
practitioners, including metamizole, opiates and combinations such as butalbital plus aspirin
plus caffeine or butalbital plus aspirin plus caffeine plus codeine . Notably, however, the use
of these medications can be associated with  several  AEs; therefore, caution is needed with
their  used.  Butalbital-containing combinations  pose a risk of overuse and development  of
medication overuse headache (MOH) . Opioids also have a sedative effect, which may put
patients at risk. American and European guidelines both suggest that the use of opioids should
be limited because of limited efficacy, sedative effects and the risk of abuse . 
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2.1. Analgesics (NSAIDs, paracetamol)
For mild-to-moderate migraine headache attacks, the drugs of first choice are analgesics .
2.1.1. Efficacy of NSAID monotherapy
As  an  irreversible  cyclooxygenase-1  (COX-1)  inhibitor  that  blocks  the  production  of
thromboxane A2, aspirin decreases platelet aggregation  (Table 1). Aspirin is widely used as
an  antiplatelet  drug,  but  it  is  an  effective  medication  in  acute  migraine  therapy as  well.
Evidence  indicates  that  platelet  aggregation  is  increased  in  migraineurs  both  ictally  and
interictally,  which  is  possibly  related  to alterations  in  eicosanoid  synthesis  in  platelets  .
Aggregating  platelets  can  lead  to  serotonin  release,  which  may  contribute  to  migraine
pathomechanism . Another important aspect is the increased risk of migraineurs to develop
ischaemic stroke and myocardial infarction, particularly in migraine with aura. The risk for
ischemic  stroke  is  especially  high  in  women  taking  oral  contraceptives  and  smoking  .
Furthermore,  aspirin  may  exert  its  beneficial  effects  in  migraine  through  local  analgesic
effects, the modulation of cerebral serotonin metabolism as well as the inhibition of central
trigeminal activation as demonstrated in a feline model of migraine . In humans, following
trigemino-nociceptive stimulation, aspirin acted on central pain processing structures such as
the anterior cingular cortex and the secondary somatosensory cortex . The number needed to
treat (NNT) to achieve complete freedom from pain was 8.1 for 900 mg or 1000 mg aspirin
tablets or soluble formulations, which proved to be superior to placebo  .  The efficacy of
effervescent aspirin was significantly better than that of placebo: a pain-free state at 2 h was
achieved in 27.1% versus 15.1% for placebo .
Diclofenac is a phenylacetic acid derivative with a higher affinity for COX-2 inhibition than
for COX-1 .  In addition to COX inhibition,  however,  acid-sensing ion channels  represent
another possible target of diclofenac in migraine, as the drug was able to directly inhibit their
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activity and expression in sensory neurons in dorsal root ganglion of rats, which mechanism
can also counteract pain . Accordingly, local application of diclofenac into migraine-related
CNS  structures  e.g.  thalamus,  hypothalamus  and  nucleus  raphe  magnus  attenuated  pain
transmission in experimental animals . Its available formulations include tablets, powder and
intravenous injections, which possess different pharmacokinetic parameters. In different phase
clinical trials, both diclofenac potassium and epolamine were significantly more effective than
placebo for the acute treatment of migraine either by relieving the pain or by diminishing the
migraine-related  symptoms  .  Diclofenac  epolamine  led to  a  pain-free condition  at  2  h in
45.8% of the patients, as compared with 25.1% for placebo . Diclofenac potassium powder
achieved the same effect  in 24.7% versus 11.7% for placebo .  Light  hypersensitivity was
reduced in 31.4%, noise hypersensitivity in 31.1%, nausea in 20.4% and vomiting in 4.9% for
diclofenac epolamine,  in comparison with 20.1%, 14.8%, 4.9% and 2.6% respectively,  for
placebo. Diclofenac is considered to be an effective anti-migraine drug, especially in mild-to-
moderate migraine attacks .
Ibuprofen  represents  another  compound  in  the  NSAIDs  group.  In  addition  to  its
antinociceptive  effect  achieved  via  COX  inhibition,  but  experimental  data  indicate  that
ibuprofen  is  also  capable  of  preventing  pain  behaviour  induced  by  N-methyl-D-aspartate
(NMDA) activation . Ibuprofen (R/S) has two enantiomers: the S(+) enantiomer is a strong
prostaglandin synthesis inhibitor, while the R(-) enantiomer is less active . A meta-analysis
revealed  that  ibuprofen in  doses of  200 or  400 mg was effective  for  pain relief  in  acute
migraine: the NNT to achieve a pain-free state at 2 h for 200 mg ibuprofen was 13, and for
400 mg ibuprofen was 9 . Another study confirmed that the pain was reduced to mild or none
in 41.7% after 200 mg ibuprofen, and in 40.8% after 400 mg as compared with 28.1% after
placebo .
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Naproxen is a stereochemically pure NSAID of the 2-arylpropionic acid class . It is a non-
selective  inhibitor  of  COX-1  and  COX-2  .  Naproxen  is  presumed  to  exert  its  effect  in
migraine  by influencing  the  trigeminovascular  system (TS).  In  vitro  studies  revealed  that
naproxen  dose-dependently  blocks  the  ATP  receptors  (P2X3)  in  cultured  rat  trigeminal
neurons , and it was shown to inhibit the peripheral sensitization of meningeal nociceptors in
rats in vivo . In another experimental study, parenteral administration of naproxen blocked the
activation of central trigeminovascular neurons in the trigeminal nucleus caudalis (TNC) in
rats, indicating the potential of naproxen on central sensitization .
A  meta-analysis  revealed  that  naproxen  sodium in  a  dose  of  500  or  825  mg  was  more
effective  than  placebo  in  reducing  the  intensity  of  migraine  headache  and  in  improving
migraine-associated symptoms; the NNT to achieve a pain-free condition was 10, which is
comparable  with  that  of  400  mg  of  ibuprofen  .  Naproxen  was  significantly  better  than
placebo: the relative risk to achieve a pain-free response within 2 h was 4.26 for 825 mg of
naproxen versus 1.83 for 500 mg . 
2.1.2. Efficacy of paracetamol (acetaminophen)
The exact mechanism of action of paracetamol is still debated. While its inhibitory effect on
the COX-1 and COX-2 metabolism is  widely accepted,  paracetamol  also exerts  a  central
analgesic effect is mediated through the activation of descending serotoninergic pathways,
and the inhibition of thalamic nociceptive activity . Furthermore, paracetamol is also capable
of inhibiting hyperalgesia after activation of NMDA or substance P receptors . A randomized
placebo-controlled trial demonstrated that a paracetamol dose of 1000 mg was significantly
more effective  than placebo for the relief  of acute  migraine  pain and migraine-associated
symptoms  ,  the rate  of drug-related AEs in the paracetamol-treated  group was 10.2%, as
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compared with 14.8% in the placebo group. It reduced the migraine pain to mild or none in 2
h in 52%, as compared with 32% for placebo; the NNT was 12 . 
2.1.3. Safety and tolerability of NSAIDs and paracetamol
The AEs of aspirin are generally mild or moderate and transient, and the most affected organ
system are the GI tract and the nervous system  (Table 2 and Table 6).  The well-known
aspirin-associated gastrointestinal (GI) disturbances include gastric ulcer, which is thought to
be caused by suppression of prostaglandin synthesis by aspirin.  In low-dose aspirin users,
most of the gastric ulcers are asymptomatic . A high single-dose (1000 mg) of aspirin for
acute migraine treatment affected the GI system in 5.9% of the cases (number-needed-to-
harm, NNH: 42) . Data from a meta-analysis of the use of effervescent 1000 mg aspirin for
the acute treatment of migraine headache demonstrated an overall AE rate of 12%, of which
3.6% were GI and 1.8% affected the nervous system . Another study demonstrated that 38%
of the AEs reported following a single 900 mg dose of mouth-dispersible  aspirin  for the
treatment of migraine attack were GI disturbances on the day of treatment. Subsequent to the
intake of aspirin, dyspepsia, nausea and vomiting occurred as GI symptoms . The non-GI AEs
observed included tinnitus, coughing and taste perversion .  There are data indicating that
the incidence of GI AEs after aspirin administration is comparable to that following
ibuprofen administration .
Diclofenac is associated with a low rate of side-effects, which are mostly mild and transient
and occur at  the same rate  as with placebo .  Among the outcomes of phase III trials,  no
serious AEs were reported. The most common AEs were GI, e.g. nausea (around 3%), or
nervous system-related, e.g. dizziness (around 1%) . 
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A randomized controlled trial demonstrated that drug-related AEs of ibuprofen 200 mg and
400 mg occurred in 27.8% and 26% of the cases, respectively. The rates of GI-related AEs
were reported to be as follows: nausea 24.5% (200 mg) and 21.5% (400 mg), vomiting 4.2%
(200 mg)  and 4.5% (400 mg),  and abdominal  pain 1.4% (200 mg) and 0.4% (400 mg) .
Ibuprofen furnishes effective treatment for acute migraine with only mild and transient AEs . 
The safety profile of naproxen sodium was worse than that of placebo (pooled risk ratio 1.29,
95%  confidence  interval,  CI  1.04-1.60,  P=0.02).  The  observed  AEs  were  nausea  (1%),
dizziness  (2%),  dyspepsia/abdominal  pain  (2%),  chest  tightness  (2%) and tinnitus  (2%) .
Although naproxen sodium is effective in reducing migraine pain and migraine-associated
symptoms relative to placebo, its NNT is high; therefore, not every patient can benefit from
its use. Generally, however, naproxen is safe and the associating AEs are rare.
The most common AEs of paracetamol occurred in the special senses (hyperacusis 19.2%,
photophobia  15.8% and  nausea  14.7%).  A  serious  AE (liver  toxicity)  can  emerge  when
paracetamol is taken regularly and in large doses (more than 4 g per day) . Paracetamol in a
dose of 1000 mg is superior to placebo in the treatment of acute migraine, and its AEs do not
differ significantly from those of placebo .
2.1.4. NSAIDs in combination with caffeine
The fixed combination of 250 mg aspirin + 200 mg paracetamol + 50 mg caffeine is effective
in acute migraine treatment and is ranked Level A in the EFNS guidelines . Another study
demonstrated that the combination 500 mg aspirin + 500 mg paracetamol + 130 mg caffeine
was superior to 400 mg ibuprofen, and to the ingredients of the combination administered
alone or in dual combination for migraine pain relief (the pain was reduced to mild or none in
67% of the cases for the combination versus 62% for ibuprofen) . Caffeine exerts its effect as
an adenosine antagonist, through which it is also able to stimulate cholinergic neurons and to
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inhibit COX-2 protein synthesis . Experimental data indicate that the combination of aspirin,
paracetamol and caffeine has a synergistic effect on COX inhibition . Moreover, caffeine not
only  potentiates  the  analgesic  effect,  but  may  also  prevent  the  sedating  AE  of  these
substances,  e.g.  the  sedating  effect  of  butalbital  and  codeine  in  the  fixed  drug
combination of aspirin+butalbital+codeine+caffeine . On the other hand, a dose of over
200-300 mg caffeine may induce dysphoria, vomiting or motor unrest . Another important
aspect of the potentiating effect caffeine is that it can permit the reduction of analgesic dose,
which  may  also  reduce  the  risk  of  potential  AEs  such  as  liver  toxicity  induced  by
paracetamol.  Gastrointestinal  AEs are well-known risks of analgesics,  and clinical  studies
indicated that the combination of paracetamol+aspirin+caffeine was associated with a higher
risk of gastrointestinal complaints than either ibuprofen or sumatriptan. However, these AEs
were generally mild, and no serious AEs have been reported . The presence of caffeine does
not increase renal toxicity, and there is no evidence of a greater risk of medication overuse
headache or physical dependence in a combination with analgesics than for caffeine alone .
The multicomponent drugs may be generally more effective than the single substances and are
generally not associated with a higher risk of AEs. 
2.1.5. NSAIDs in combination with antiemetics
NSAIDs such as aspirin, diclofenac, ibuprofen, naproxen and paracetamol are often combined
with  antiemetics  with  the  aim of  diminishing  acute  migraine  headache.  Antiemetics  may
increase the extent of NSAID absorption from the GI tract. Metoclopramide and domperidon
are suggested for the purpose of Level B recommendation . Various routes of administration
of  metoclopramide  are  available,  e.g.  oral,  suppository,  intramuscular,  intravenous  and
subcutaneous.  Metoclopramide  is  usually  well  tolerated  is  generally  associated  with  mild
side-effects such as drowsiness, restlessness or bowel disturbances . Metoclopramide is an
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antagonist  of  central  dopaminergic  receptors;  therefore,  especially  at  higher  doses,
extrapyramidal  side-effects  may  develop  such  as  tardive  dyskinesia,  drug-induced
parkinsonism and akathisia  .  Interestingly,  tardive dyskinesia  was more severe in diabetic
patients compared to non-diabetics . In patients with renal impairment, the risk of developing
extrapyramidal  side-effects  is  higher,  therefore  the  dose  of  metoclopramide  has  to  be
reduced .  Rapid intravenous administration  of metoclopramide  may induce  cardiac  arrest,
representing a  rare  but  serious AE .  Domperidone,  another  antiemetic  has  a better  safety
profile as it does not cross the blood-brain barrier and therefore extrapyramidal side-effects do
not develop in adults .
2.1.6. NSAIDs and cardiovascular risk
There has been no systematic review of cardiovascular AEs following the use of NSAIDs in
migraine  treatment.  The  relationship  between  the  administration  of  NSAIDs  and
cardiovascular AEs is still debated. Awareness of the potential cardiovascular risks of NSAID
users were highlighted by the VIGOR study in 2000, which reported that rofecoxib increased
the risk of myocardial infarction . A large UK meta-analysis led to the conclusion that the
vascular  risk  of  high-dose  diclofenac  and  possibly  ibuprofen  was  comparable  to  that  of
selective COX-2 inhibitors (coxibs), while high-dose naproxen had less vascular risk than that
with other NSAIDs . Major coronary events were more frequent with coxibs, diclofenac and
ibuprofen, whereas major vascular events were associated only with coxibs and diclofenac.
Naproxen did not increase the risk of vascular death, major coronary events or major vascular
events as serious AEs in comparison with coxibs and diclofenac . The risk of heart failure was
higher  in  diclofenac,  ibuprofen  and  naproxen.  Neither  NSAID  was  associated  with  an
increased risk of stroke . In spite of these data, the US Food and Drug Administration (FDA)
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has recently (February 2014) reported that the current data did not indicate that naproxen had
a lower risk of thrombotic events than other NSAIDs .
The relative  risks or odds ratios  (OR) associated with NSAIDs to develop cardiovascular
events are below 2 . Randomized clinical trials and observational studies have suggested that
the risk of cardiovascular events related to the use of NSAIDs is clearly dose- and duration-
dependent .
2.1.7. Summary of NSAIDs
In general, the use of NSAIDs is associated with low rates of AEs, generally manifesting in
nausea, peptic ulcer, dizziness, tinnitus, hepatotoxicity and nephropathy as the most common.
The  contraindications  of  the  administration  of  NSAIDs  are  peptic  ulcer,  bowel  diseases,
haemorrhagic  stroke and the third trimester  of pregnancy .  However,  the first-line  use of
NSAID/aspirin  medication  proved  to  be  10%  among  diagnosed  gastroesophageal  reflux
disease (GERD) patients. In one study, 22% of migraineurs reported the existence of GERD .
The  risk  of  developing  NSAID-related  GI  complications  is  significantly  higher  in  older
patients, in case of pre-existing gastric ulcer, in case of concomitant use of oral anticoagulants
or  corticosteroids,  among  alcoholics  or  smokers,  as  well  as  in  patients  with Helicobacter
pylori infection . Non-selective NSAIDs pose a significantly higher risk of GI toxicity than
COX-2-selective ones, and theit toxic effect increases with dose. The risk of dying of peptic
ulcer bleeding is estimated to be around 5% in Europe, US and Asia as well . The presence of
gastric ulcer represents an absolute contraindication for NSAIDs. In the presence of other risk
factors,  the  use  of  these  medications  needs  to  be  carefully  considered,  and  caution  is
recommended. Among the other GI-related AEs, nausea and vomiting are most frequently
associated with the use of ibuprofen, and less frequently with naproxen and diclofenac.
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In patients with high cardiovascular risk, caution is needed when considering NSAID therapy.
In  such  a  case,  naproxen  is  probably  a  better  choice  than  diclofenac  or  ibuprofen.
Cardiovascular risk related to NSAIDs is most likely dose-dependent; therefore, if low doses
are used to treat a migraine attack, the associating risk of developing major vascular events is
low. The overuse of NSAIDs involves a low risk of transformation from an episodic state to a
chronic form of migraine .  
2.2. Ergot alkaloids
One of the oldest groups of medication for the treatment of migraine attack are the ergot
alkaloids. The first publication relating to the use of ergotamine tartrate for migraine therapy
dates from 1934 and the administration of DHE was reported in 1945 . DHE and ergotamine
display  broad  monoaminergic  receptor  affinity  (e.g.  5-hydroxytryptamine  (5-HT)  1B/1D/1A
agonists, dopamine D2 agonists and epinephrine agonists) (Table 3). Ergotamine was capable
of blocking neurogenic inflammation by preventing plasma extravasation in the dura mater of
rats . Regarding DHE, evidence indicates that it is able to influence the pain-processing nuclei
in the brainstem . The various routes of administration available for DHE include intravenous,
intramuscular, intranasal, subcutaneous and orally inhaled. Oral DHE tablets are not available
because of the poor bioavailability . 
DHE administered by the intravenous, intramuscular, subcutaneous, intranasal route or orally
inhaled is more effective than placebo for the treatment of a migraine attack . Orally inhaled
administration  of  DHE was  achieved  at  2  h  pain  relief  in  59% of  the  migraine  patients
compared to 35% in placebo group . Ergotamine is also an effective therapeutic option for
diminishing migraine pain . In one prospective clinical trial, the AEs following intravenous
DHE  administration  were  nausea  (72%),  light-headedness  (33%)  and  leg  cramps  (23%)
(Table 5 and Table 6). Subsequent to an intranasal DHE formulation, the commonly observed
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AEs were rhinitis (26%), nausea (10%) and an altered sense of taste (8%) . One the other and,
frequent  use  of  ergotamine  has  been  associated  with  the  development  of  pericardial,
pulmonary  and  retroperitoneal  fibrosis.  These  rare  complications  are  suggested  to  be
serotonergic-related idiosyncratic responses. Fibrotic AEs have been reported in connection
with DHE only in rare cases .
Serious AEs after the use of DHE are relatively rare. Vasoconstrictive AEs are not common
after  any  DHE  formulation,  comparatively,  arterial  vasoconstriction  was  frequent  when
ergotamine was used . This difference can be explained by their different pharmacological
properties, as DHE is a less potent arterial vasoconstrictor than ergotamine, even though they
induce venoconstriction in a similar level . Ergotamine is therefore contraindicated in cases of
vertebrobasilar  migraine  or  prolonged aura  .  A recent  systematic  review of  observational
studies revealed that the pooled OR of serious ischaemic events was 2.28 (95% CI 1.18-4.41)
for ergotamine compounds (ergotamine or DHE) administered for acute migraine treatment .
The  risk  of  developing  ischaemic  stroke  is  elevated  in  women  with  migraine  with  aura,
especially  if  they  smoke  or  take  hormonal  contraceptives  .  Therefore,  in  those  women
suffering from migraine with aura who smoke and take hormonal contraceptives at the
same time, ergotamine and DHE are not recommended.
Ergotamine is more likely to cause medication overuse headache (MOH) . This difference can
be explained the different pharmacokinetic profiles of DHE and ergotamine, The elimination
of DHE is biphasic and has a long elimination half-life . The availability of the various routes
of administration of DHE is favourable for the daily clinical practice, and DHE is effective
and well tolerated in the treatment of migraine attacks.
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2.3. Triptans
Triptans are the drugs of first choice for the acute treatment of moderate-to-severe migraine
headaches  .  Seven  different  triptans  are  currently  available:  sumatriptan,  eletriptan,
zolmitriptan, rizatriptan, naratriptan, almotriptan and frovatriptan (Table 4).
2.3.1. Efficacy of triptan monotherapy
Sumatriptan is a selective 5-HT1B/1D/1F receptor agonist and it also has a potency to influence
serotonergic neurotransmission in the brainstem, predominantly in the dorsal raphe nucleus
(Table  4).  Oral  sumatriptan  proved to  be  more  effective  than  placebo,  and the  Cochrane
Database reviews reported that sumatriptan by any route of administration was superior to
placebo as concerns the efficacy outcome .  Oral 50 mg sumatriptan provided complete pain
relief in 28% of the patients, as compared with 11% for placebo .  The most effective dose of
sumatriptan for pain relief at 2 h was 100 mg orally (NNT 3.5), 6 mg subcutaneously (NNT
2.1),  20 mg intranasally (NNT 3.5) or 25 mg rectally (NNT 2.4) . The efficacy results from
clinical trials of the iontophoretic sumatriptan patch revealed that the freedom from pain at 2 h
was NNT 11.1 . 
Eletriptan  is  a  selective  5-HT1B/1D/1F receptor  agonist,  and  in  preclinical  studies  has  been
demonstrated to modulate the activation of the trigeminovascular system . Eletriptan is more
lipophilic  than  other  triptans  and  readily  reaches  the  central  nervous  system  (CNS).   It
demonstrates significant efficacy in the acute treatment of migraine to achieve complete pain
relief in 2 h in doses of 40 and 80 mg versus placebo (27%, 27% and 4%, respectively) .
Zolmitriptan, a member of the tryptamine-based drug family, binds to 5-HT1B/1D and 5-HT1A/1F
receptors, and it is also influences trigeminal pain processing, as indicated by the inhibition of
the nociceptive blink reflex response . It is available as an oral formulation (2.5 mg and 5 mg
tablets) and a nasal spray (5 mg). Zolmitriptan is effective relative to placebo in the acute
16
treatment of migraine .  Oral zolmitriptan in a dose of  2.5 mg or 5 mg achieved complete
headache relief at 2 h, with the same efficacy as sumatriptan 50 mg (66%, 67% and 68%,
respectively). 
Rizatriptan  is  a  potent  agonist  with  high  affinity  for  the  5HT1B/1D receptor,  and  it  exerts
inhibitory effects on nociceptive neurotransmission in the trigeminal nucleus caudalis and on
the activation of the nucleus raphe magnus after trigeminal activation . Oral 5 mg and 10 mg
tablets and a disintegrating wafer formulation containing 10 mg are available . Rizatriptan
proved more effective than placebo in migraine attack therapy (pain-free 40-42% versus 7-
10% for placebo) . 
Naratriptan  has  high  affinity  for  5-HT1B/1D/1F receptors  exerting  its  beneficial  effect  on
trigeminovascular neurons . Naratriptan has higher bioavailability than those of other orally
administered triptans . Naratriptran is effective relative to placebo in the acute treatment of
migraine: the headache relief at 2 h was 52% versus 31% with placebo . 
Almotriptan acts on the 5-HT1B/1D/1F receptors. Almotriptan in a dose of 12.5 mg is superior to
placebo for the acute treatment of migraine: the relative risk to achieve complete pain relief
was 2.15 compared to placebo . 
Frovatriptan exerts potent effects on the 5-HT1B/1D receptors, while it has moderate affinity for
5-HT1A/1F receptors . The efficacy of oral frovatriptan to achieve pain relief within 2 h in acute
migraine therapy was better than that of placebo: 37–46% vs. 21–27% . 
2.3.2. Combination of triptans and NSAIDs
The combined administration of sumatriptan with naproxen represents an effective treatment
of migraine attacks, providing better pain relief than either of the two drugs applied alone in
the same dose, and exhibiting good tolerability at the same time . Furthermore, in migraineurs
who  displayed  poor  response  to  triptans  administered  alone,  this  combination  was
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significantly more effective than placebo . This combination was generally well tolerated,
with the most frequent AE being chest pain, but no serious AEs were reported . Similarly,
combinations of rizatriptan plus rofecoxib, almotriptan plus aceclofenac or frovatriptan plus
dexketoprofen all exhibited better efficacy than the listed drugs alone, while the frequency of
AEs was not significantly different  for either  combination compared to the corresponding
triptan  alone  .  The  good  efficacy  of  frovatriptan  plus  dexketoprofen  was  also  proved  in
menstrually-related migraine . These studies all confirmed that the combination of triptans
with NSAIDs is superior to the monotherapy in case of each of these medications, while the
tolerability and safety profiles are comparable.
2.3.3. Safety and tolerability of triptans
Sumatriptan-associated  AEs  vary  with  the  formulation.  AEs  were  generally  found  to  be
infrequent after oral administration, and included fatigue (6%), paraesthesia (5%), heaviness
(4%)  and  chest  pain  (3%)  (Table  5  and  Table  6).  Following  the  intranasal  form,  taste
disturbances and disgeusia occurred in up to 30% of the cases, while after the subcutaneous
form, local reactions and flushing were most common . Use of the transdermal patch was
associated with skin irritation (8%), pain (23%) and paraesthesia (12%). The suppository form
has been reported to cause sedation in 6% of the cases . The AEs tend to be more common
following  administration  via  the  injectable  route  and  following  oral  or  intranasal
administration of higher doses . 
The AEs of eletriptan are dose-related: following the 20 mg dose, they were equivalent to
those after the placebo, the 40 mg dose led to only a slightly higher frequency (2%) than after
the placebo, while  the 80 mg dose resulted in increased rates of AEs (1-7%) .  The most
frequent AEs were asthenia (20 mg: 4%; 40 mg: 5%; 80 mg: 12%), nausea (20 mg: 5%; 40
mg: 7%; 80 mg: 10%), dizziness (20 mg: 3%; 40 mg: 5%; 80 mg: 7%), chest tightness (20
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mg: 1%; 40 mg: 2%; 80 mg: 5%) and somnolence (20 mg: 3%; 40 mg: 5%; 80 mg: 6%) .
Eletriptan has a very high safety and tolerability profile .
The AEs observed following a 5 mg dose of zolmitriptan were asthenia (14%), nausea (12%),
paraesthesia (11%), dizziness (11%), somnolence (10%) and chest tightness (7%) . 
The most  common (fewer than 10% of the migraine patients)  dose-related AEs of 10 mg
rizatriptan were nausea (4%), somnolence (4%), dizziness (2%) and asthenia/fatigue (2%) .
The AE profile of naratriptan includes mainly mild AEs, indicating that naratriptan is well
tolerated . The most frequent AEs of 2.5 mg naratriptan: nausea (7%) vomiting (7%) and
tingling (3%) . 
Almotriptan (12.5 mg) does not differ significantly in any AE from placebo, e.g. dizziness
(2.7%), paraesthesia (2.7%), nausea (1.9%), somnolence (1.6%) and vomiting (1.6%) . 
The most  frequent  treatment-emergent  AEs of   2.5 mg frovatriptan  were  dizziness  (8%),
fatigue (5%), paraesthesia (4%), flushing (4%), skeletal  pain (3%), dry mouth (3%), chest
pain (2%) and dyspepsia (2%) . 
2.3.4. Summary of triptans
All the triptans have attained the level A recommendation in acute migraine therapy.  The
chest-related AEs are chest pain, chest tightness, chest heaviness and chest pressure . The
explanation of the observed chest pain (3-5% of the triptan users) without ECG abnormalities
is  still  unknown.  The  relevant  hypotheses  include  an  oesophageal  spasm,  an  intercostal
muscle spasm, pulmonary vasoconstriction and even anxiety . Subcutaneous sumatriptan has
been  associated  with  25%  more  AEs  than  placebo,  whereas  naratriptan  and  almotriptan
displayed similar rates of AEs as in the case of placebo . The AEs of triptans are generally
mild and transient, e.g. dizziness, somnolence, tiredness, dry mouth, impaired concentration,
paraesthesia,  a  warm  sensation,  palpations,  a  facial  flush  and  chest  tightness  .  The
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contraindications  to triptans  are  hemiplegic and brainstem migraine,  a  transient  ischaemic
attack,  ischaemic  stroke,  ischaemic  heart  disease,  Prinzmetal’s  angina,  peripheral  vascular
disease (e.g. Raynaud’s disease), uncontrolled hypertension, pregnancy, lactation, the use of
ergot  alkaloids,  the use of  MAO inhibitors,  association  with selective  serotonin re-uptake
inhibitors,  severe  renal  or  liver  failure,  and  hypersensitivity  to  triptans  .  Postmarketing
surveillance data and the experience of physicians suggest that in real-life practice triptans
reach very good or good ranges of efficacy and safety among a broad spectrum of migraine
patients .
 
3. Pregnancy and breastfeeding in women with migraine
The  safe  and  efficacious  treatment  of  pregnant  and  breastfeeding  migraineurs  poses  a
considerable challenge. The possible AEs and therefore the recommendations are different for
the periods of pregnancy and lactation.
For  acute  migraine  treatment,  only  paracetamol  is  allowed  during  all  three  trimesters  of
pregnancy. NSAIDs can be given in the second trimester and should be avoided in the third
trimester . The administration of NSAIDs  during the third trimester causes an increased risk
of constriction of the ductus arteriosus Botalli .  Following the use of aspirin in first trimester
pregnancy, gastroschisis was confirmed as a malformation . The intake of antiemetics such as
metoclopramide during pregnancy does not increase the risk of birth defects. Ergotamine and
DHE  are  contraindicated  during  pregnancy  due  to  their  vasoconstrictive  and  uterine-
contracting activities . Later, triptans were launched, but they are also contraindicated in
all trimesters of pregnancy according to the manufacturers’ instruction . However, most
recent studies concluded that triptan redemption during pregnancy was not associated
with  major  congenital  malformations  or  prematurity  .  Therefore,  in  daily  clinical
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practice, the risk/benefit ratio should be carefully assessed for both the mother and the
foetus before initiating triptan therapy.
Drug safety for breastfeeding mothers is rated according to the Hale lactation risk categories
and American Academy of Pediatrics recommendations . The Hale’s criteria range from L1
(the safest) to L5 (contraindicated). During breastfeeding, aspirin is considered to be safe in
low doses, while in higher doses it is contraindicated, because it reaches high levels in infants,
and can also be associated with Reye’s syndrome . Other possible AEs related to the use of
aspirin  include  haemorrhage and metabolic  acidosis  .  Ibuprofen is  detectable  in  only low
concentrations in the maternal milk after a dosage of 400 mg, and is therefore considered safe.
Although less than 1% of naproxen is excreted into the human milk, it has a long half-life and
its use has been reported to be associated with bleeding abnormalities in the newborn; other
NSAIDs are therefore preferable (L4 possibly hazardous) . Diclofenac is probably compatible
because it is excreted in only low levels in the maternal milk, but it achieved only the L2
grade (safer) on the Hale scale. Only acetaminophen and ibuprofen reached the L1 category,
considered safest and compatible with breastfeeding . Several analgesics are combined with
caffeine, which is generally regarded as safe (L2). However, in high doses it may cause sleep
disturbances in the infant, and its use by mothers should therefore be restricted .
Metoclopramide passes into the maternal milk and could elicit extrapyramidal side-effects or
methemoglobinaemia  in  the newborn .  Its  use should be avoided during lactation  .  Ergot
alkaloids should be avoided during lactation, because the level excreted in the maternal milk
is unknown, and some data have indicated that they may inhibit  prolactin production and
lactation . 
No data are available for most triptans; only eletriptan and sumatriptan have been reported to
be in low levels of maternal milk and cause no AEs in infants, but only in small numbers of
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women . Rizatriptan has been reported to pass into the milk only in low levels in rodents;
however, human data are at present not available . 
The recommendation of  the American Academy of  Pediatrics  helps  the  physician in
counseling  a  nursing  mother  the  safest  drug  during  breastfeeding.  According  to  its
recommendations, aspirin and ergotamine can be recommended with caution, whereas
acetaminophen, caffeine, ibuprofen, naproxen and sumatriptan are usually compatible
with breastfeeding .
4. Medication overuse headache (MOH)
MOH is a secondary headache disorder with a worldwide prevalence of 1-2% . The diagnosis
of MOH can be established if a patient has headache on at least 15 days per month for more
than 3 months, and the headache can be linked to regular overuse of a headache medication .
The criteria of chronic migraine are very similar (headache present for 15 days or more per
month for at least 3 months); however, in this case at least 8 attacks have to fulfill the criteria
of migraine headache as well.  Chronic migraine can occur either in association with or
independently of MOH . The fact that medication withdrawal in MOH is generally followed
by symptomatic improvement and a decrease in headache frequency represents an important
difference,  as  in  case  of  chronic  migraine  drug  withdrawal  does  not  help  .  It  is  still
controversial whether medication overuse is a consequence of chronic headache or vice versa,
generally it cannot be decided until medications are discontinued . The uncertainty is due
to the observation that not all headache patients who overuse medication will develop MOH.
MOH can develop  following  the  intake  of  simple  analgesics  on  15 days  per  month,
whereas for triptans and ergotamines it develops after an intake on 10 days per month .
The risk of MOH is higher for triptans, which cause MOH faster and after less intake
than other pharmacons used in the treatment of acute migraine attacks. The average time
22
for the development of MOH is around 2 years in the case of triptan administration, while for
analgesics it is approximately 5 years . The American Migraine Prevalence and Prevention
(AMPP)  study  proved  that  the  extent  of  risk  of  migraine  chronification  depends  on  the
different  medications  used,  with  triptans  posing  the  highest  risk  for  developing  chronic
migraine. Interestingly, the effect of NSAIDs depends on the number of days with headache:
in patients with less than 10 headache days per month, the use of NSAIDs decrease the risk of
chronic migraine, whereas in those patients with above 10 headache days, they even increase
this risk. Combined use of NSAIDs plus triptans was not associated with an increased risk of
chronic  migraine  compared to  that  seen in  triptan  monotherapy.  Opioids  and barbiturates
dose-dependently  increase  the  risk  of  migraine  chronification  with  an  observable  gender
difference: the risk of chronification for opioids is higher in men, whereas barbiturate use
associates with an increased risk in women. Caffeine-containing combinations also increase
the risk of chronification, but not the risk of MOH . The types of overused medications
changed over the last decades.  Nowadays, triptans and NSAIDs are the most frequently
used drugs for acute migraine treatment; therefore, they became the drugs that are the
most frequently associated with MOH, with a frequency exceeding that for ergots and
butalbital combinations, which used to represent the most frequent causes of MOH in
the  past  .  A  large  population-based  study  revealed  that  the  regular  use  of  tranquilizers
increases the risk of developing MOH even 11 years later . Besides medications, several other
risk factors have been identified such as depression, anxiety, smoking and physical inactivity .
However, the exact pathomechanism of the initiation of MOH still not fully elucidated.
5. Conclusions
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Among the pharmacons currently used for the acute treatment of migraine, several NSAIDs,
ergot alkaloids and all triptans have reached the level A recommendation on the basis of their
efficacy. These drugs all have distinct safety profiles and may be associated with various AEs.
NSAIDs have a low ratio of AEs, gastric intolerance being the most frequent. Among the
ergot alkaloids,  DHE is generally better tolerated and poses a lower risk than ergotamine.
Triptans are widely used, effective medication to counter migraine attacks, and their AEs are
generally mild and transient. Caution is recommended with triptans in patients with severe
cardiovascular disease, peripheral vascular disease or cerebrovascular disease. As concerns
MOH, NSAIDs present a lower risk than those of ergots and triptans. The only drug which
can be used in all trimesters of pregnancy and during lactation is paracetamol.
6. Expert opinion
The  widely  accepted  criterion  for  effective  migraine  pharmacological  treatment  is  the
achievement  of  complete  relief  of  pain  within  2  h.  Other  important  requirements  of  the
therapy are safety and tolerability, which can additionally determine the patient compliance.
The pathomechanism of migraine,  the initiation of the attacks and the genetic background
have not yet been fully clarified, and the currently used pharmacons are in the main not aimed
at causative factors.  The use of NSAIDs in migraine is  supported by the neurogenic
inflammation  concept,  whereas  ergot  alkaloids  and  particularly  triptans  target  the
trigeminovascular system, the activation and sensitization of which represent another
widely  accepted  hypothesis  concerning  the  pathomechanism  of  migraine.  Most  the
available drugs do not (or only partly) meet the above criteria. The development of novel
pharmacons is delayed by the lack of adequate animal models, and by the fact that there are
no  migraine-specific  biomarkers  in  humans.  Another  important  point  involved  in  drug
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development  is  that  there  are  no  adequate  methods  with  which  to  predict  drug safety  in
different patients. 
The  currently  available  medications  do  not  satisfy  all  requirements  of  acute  migraine
treatment.  Several AEs can lead to loss of patient compliance,  whereas the use of several
medications require special caution in light of the comorbid conditions. In a number cases, the
therapeutic decision is difficult, e.g. when a concomitant disease contraindicates the use of a
drug class while other medications cannot be tolerated or are not effective. In daily clinical
practice, special focus has to be placed on the concomitant presence of cardiovascular and GI
disorders, as they may limit  the use of triptans or NSAIDs. As young women represent a
significant  proportion  of  migraine  patients,  pregnancy  and  breastfeeding  are  common
situations that narrow the therapeutic options. 
For  patients  who  experience  frequent  attacks  with  mild  or  moderate  headache  severity,
NSAIDs are currently recommended,  because the risk of MOH is relatively low for this
group of anti-migraine medications. Caution is needed in patients with GI disorders, where
NSAID administration may worsen the GI symptoms; in this patient subgroup, triptans must
be considered. There is still insufficient evidence regarding the cardiovascular risk following
NSAID use in migraine. More studies are needed to clarify the possible relationships between
NSAIDs and cardiovascular events. 
Triptans are recommended for patients with for patients with more severe migraine pain,
but the risk of development of MOH is higher after triptans than after NSAIDs. Interestingly,
although triptans  are  very effective  for  acute  migraine  treatment,  a  12-year  Danish study
revealed that the use of triptans did not decrease the duration of absence from work . Triptans
generally induce only modest side-effects and have a well-established safety record. However,
there is also evidence that 1000 mg of aspirin has the same efficacy as 50 mg of sumatriptan,
and aspirin has a better side-effect profile . Among the seven triptans, almotriptan seems to be
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the  best  tolerated .  The  tolerability  of  triptans  cannot  be  predicted  from  their
pharmacokinetic profile . Postmarketing surveys have demonstrated an acceptable benefit-risk
ratio  of triptans,  which justifies  the prescription  of these drugs for the acute treatment  of
migraine, and furthermore the patients wish to continue this type of therapy.  
Ergot alkaloids are currently not the drugs of first choice; they are mainly used in patients
who do not benefit from triptans or who cannot tolerate them. Importantly, the development
of MOH is very rare  among DHE users,  but  frequent  with ergotamine  .  In  patients  with
migraine with aura or with vascular risk factors, ergots are also not recommended. 
The safety profile of different medications is different for pregnancy and lactation. During
pregnancy, triptans and ergots are contraindicated, so NSAIDs are during the third trimester
of  pregnancy.  Paracetamol  is  the  only drug that  can  be  recommended  during  pregnancy,
whereas during lactation paracetamol and ibuprofen are applicable. 
The future goal of drug development must be the creation of potent drugs with a favourable
safety  profile,  which  are  well  tolerated.  In  recent  years,  a  number  of  different  new
formulations  have  been  developed,  e.g.  a  transdermal  iontophoretic  patch,  a  needle-free
subcutaneous  device,  rapidly  disintegrating  oral  formulations,  oral  inhalation  forms,
orodispersible  granules,  effervescent  tablets  and  micronized  tablets.  These  administration
routes may be associated with better tolerability profiles. Although such formulations are as
yet available for only a few pharmacons, in the near future they should be made available for
more of the drugs currently used in the acute therapy of migraine.
The ultimate goal in the next 5 years of treatment is the attainment of personalized medicine,
i.e.  pharmacotherapy  tailored  to  the  individual  migraineur.  To  achieve  this,  the
pathomechanism and genetic background must be clearly elucidated, and reliable biomarkers
must  be  established.  As  the  currently  utilized  drugs  do  not  address  the  pathomechanism
perfectly,  novel  targets  must  be  identified  for  drug  development.  Calcitonin  gene-related
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peptide receptors appear to be good targets for the acute treatment of migraine, but the safety
profile is not yet favourable. Another novel option would be the application of neurally acting
anti-migraine agents, but the currently available drugs frequently result in AEs in the CNS.
Future investigations are necessary to overcome these limitations.
Recent preclinical data point to the possible roles of the kynurenine system as well as pituitary
adenylate-cyclase  activating  polypeptide  (PACAP)  and  its  receptor  .  They  are  promising
targets for the development of novel pharmacons, which may also have a beneficial safety
profile. 
Future research addressing these outstanding issues will hopefully promote progress in the
daily  clinical  practice  through  the  determination  of  beneficial  pharmacotherapy  for  the
individual migraine patient. 
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Article highlights box
 Migraine  is  a  primary  neurovascular  headache  disorder,  the  pharmacological
management of which is challenging. 
 The  acute  treatment  of  migraine  consists  in  both  aspecific  and  specific
pharmacological therapy; drugs achieving the Level A recommendations are discussed
in this review. 
 The safety profile of the different drugs used in the acute therapy of migraine are
discussed, including NSAIDs, ergot alkaloids and triptans.
 The regular excessive use of these drugs is accompanied by the risk of development of
medication overuse headache.
 Special focus is placed on the pharmacological treatment of migraine attacks during
pregnancy and breastfeeding.
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